Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seqirus H5N8 vaccine in prior H5N1-vaccinated vs H5-naive adults
2025-522116-16-00Phase 4Completed
- Sponsor
- University of Antwerp
- Start
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 4 trial of aH5N8c in Avian Influenza (AI) (2 arms), sponsored by University of Antwerp. Primary endpoints: Hemagglutination inhibition (HI) antibody titers against H5N8 clade 2.3.4.4b at baseline and post-vaccination and Microneutralization (MN) antibody titers against H5N8 clade 2.3.4.4b at baseline and post-vaccination. Started Oct 2025; status: completed.
02
Drugs
aH5N8c
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on 2025-522116-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522116-16-00.